BTIG Maintains Buy on Guardant Health, Raises Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Mark Massaro maintains a Buy rating on Guardant Health (NASDAQ:GH) and raises the price target from $45 to $50.
July 30, 2024 | 4:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BTIG analyst Mark Massaro maintains a Buy rating on Guardant Health and raises the price target from $45 to $50.
The Buy rating and increased price target from a reputable analyst can boost investor confidence and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100